Basics for Improved Use of Phages for Therapy

Area of Science:

• Microbiology
• Biotechnology
• Nanomedicine

Background:

• Therapeutic phages and phage-derived drug delivery vehicles (DDVs) require enhanced blood persistence for efficacy.
• Current phage therapy success is limited by low phage persistence, hindering targeted delivery to pathogens or tumors.
• Phage persistence is key for both direct phage therapy and phage-based DDVs.

Purpose of the Study:

• To investigate phage persistence in murine blood and its implications for phage therapy and DDVs.
• To evaluate the effectiveness of screening strategies for identifying phages with high blood persistence.
• To explore the biodistribution and tumor tropism of persistent phages.

Main Methods:

• Comparative analysis of phage persistence in murine blood using co-inoculation and separate assays.
• Screening of coliphages T3, T7, and T4, and Pseudomonas chlororaphis phage 201phi2-1 for blood persistence.
• Assessment of phage T3 biodistribution to murine organs and tumor tropism in xenografted human oral squamous cell carcinoma.

Main Results:

• Coliphage T3 exhibited significantly higher blood persistence than coliphage T7, with coliphage T4 showing even greater long-term persistence.
• Pseudomonas chlororaphis phage 201phi2-1 demonstrated relatively low persistence.
• Highly persistent phage T3 dispersed to multiple murine organs and showed tropism for epithelial tumor tissue.

Conclusions:

• Increased phage persistence is essential for successful phage therapy and phage-based DDVs.
• Developing rapid and effective screening methods for phage persistence and dispersal is critical.
• Phage T3's properties suggest potential for therapeutic applications, but its dispersal necessitates careful consideration for DDV use.